Blue Horseshoe Stocks: NEPT Review & More

Neptune Technology & Bioresources, Inc. NEPT

To start off the new calendar year on a high note, we’d like to track back to a stock we placed on our radars on the morning of November 28th, and recap the solid bullish performance that followed.

NEPT has been in a general uptrend ever since our alert, and is showing a strong sign that it may continue. Subsequent to our initial report, we observed a low of 1.30 in the stock, and as of the new high achieved to close out last week at 2.44. it marked an increase of 88%

We’ll continue to observe this stock, and will want to see it maintain support at or above the 2.20-area on any pullbacks.

INSYS Therapeutics, Inc. INSY

We formulated an options trading idea for the INSY 01/19 $8 and $9 Calls on Wednesday morning, and on Friday. mentioned that despite only moderate gains in the previous session, that we’d still be looking for our opportunity to come along.

Friday’s session facilitated some solid moves in our highlighted contracts, and current conditions suggest we could see an extension to the already significant gains that were there for the taking to close out the 2017 trading year.

The $8 Calls ran from .90-2.27, for a gain of 152%, while the $9′s traded up from .60 to 1.51, which works out to a 151% move.

INSY has traded as high as 10.25 in premarket trading today, and we will look to roll up our strike price to the $10-level if the stock holds above this morning’s premarket low of  9.75 once the session gets rolling.

Extended Watchlist:

Incoming search terms:

  • AZBY

Blue Horseshoe Stocks: Cannabis Sector Heating Up Again

Cannabis Comments

We got head-faked a little bit in terms of the cannabis sector in the past year or so. Leading up to last fall, anything even remotely tied to marijuana was going through the roof, with seemingly no end in sight. Then a regime change in Washington led to the appointment of self-avowed cannabis hater Jeff Sessions to the head of the DOJ. That led to a considerable cooling of what was previously the hottest market sector.

That being said, it has been business as usual for companies operating in the space in places that have taken the step of ending prohibition. Growth is happening all around, and the investment community has taken notice. The cannabis sector is showing signs of heating up once again, so we want to return to some of the plays we’ve covered in the past and highlight a few that could stand to see some good moves in the days and weeks ahead.

Dewmar International, Inc. DEWM – We just signaled our interest in DEWM in Friday morning’s premarket report, and the stock made a solid two-session swing. From Friday’s low of .0108 to .0163 yesterday, marking a move of 51% We’ll want to continue to track its movements,particularly after this morning’s news.

DEWM announced today that it filed a provisional patent with the US Patent and Trademark Office for the treatment of lung cancer with cannabinoids, so that’s going to be another interesting storyline to follow with respect to DEWM.

Also going on our refreshed cannabis watchlist of previously tracked stocks will be PNTV, POTN, MCIG, MCOA, and TRTC.

Netflix, Inc. NFLX – Options

We’re always looking for a good post-earnings options play and we may have one with NFLX this morning. Up 10% in premarket trading on a solid beat, we’re going to be looking for a potential dip-and-rip scenario that could lead to some hefty intraday moves. Our targets are going to be the NFLX Weekly $172.50-180 Calls.

Extended Watchlist:

Blue Horseshoe Stocks: News Plays & Special Reminder

Aeterna Zentaris, Inc. AEZS

AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.

Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.

The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)

Zosano Pharma Corp. ZSAN

Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%

This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.

The chart also has some attractive features which we’ve pointed out on the snapshot below:


To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!

Be sure to stay locked onto your email inboxes or tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!

Extended Watchlist:

Blue Horseshoe Stocks: Strong Start to the Short Week

Even during a time of relatively high uncertainty for the markets at large, and on a short trading week, which are often more subdued than a typical week, we still managed to suss out a wide range of interesting plays in yesterday’s premarket report. Therefore, the bulk of today’s offering will be comprised of performance updates.

ViaDerma, Inc. VDRM

VDRM turned out to be the crown jewel of yesterday’s report, undergoing a massive intraday run that offered up chances at huge single session gains. We initially tagged the stock before adjourning for the holiday weekend on Friday morning. and it responded with a pop from .0048 to .0087 (+81%).

We kept it in yesterday’s report, and that’s when it really kicked into high gear, trading in a range from .00845 to an incredible new high of .0242. That worked out to a single-session romp of 186% and extended our observed gains over a two-session swing from Friday to 404%

Congrats to any of our readers who were able to hitch a ride on this wild breakout!

mCig, Inc. MCIG

As we reminded readers yesterday, MCIG was among those stocks we mentioned in our first report of 2017, subsequent to which, we would observe a low of .1599.  We then saw two weeks of a notable uptrend which brought us to yesterday’s session.

Despite already having attained a new all-time high on Friday, MCIG kept the train rolling with a solid intraday performance leading to another new high. The stock traded in a range from .388 on up to .505, a 30% push which occurred on roughly 5x the monthly average volume.

The bullish move extended our overall observed range on MCIG in just over two weeks to a whopping 216%  Any further moves from here would just be icing on the cake, but we’ll want to leave MCIG on our radar screens because a dip-and-rip pattern could be forthcoming before the week is through.

Retractable Technologies, Inc. RVP

The posting of a Form-4 filing last week, along with its positioning on the chart is what led us to focus upon RVP as a “prime bottom-play” in yesterday’s premarket report.

We were correct in doing so, timing the bottom precisely as RVP went on to rebound, trading in a range from .94 to 1.16. While that works out to a modest increase of just 23%, RVP did close just slightly below that high of day, and this morning has reached as high as 1.18. We’ll be very interest to continue tracking its activity, looking for the recording of higher highs and higher lows en route to a sustained uptrend.

PureSnax International, Inc. PSNX

Also appearing in yesterday’s newsletter was PSNX, a subpenny play which also enjoyed a sizable PPS increase on heavy volume.

The stock traded in a range from  .00239 to .0035, an intraday gain of 46%, with more than 11x the monthly average volume of shares changing hands. The price tapered slightly into a close at .0028, but provided the stock maintains support above yesterday’s swing low, we’ll remain interested in PSNX.

Delcath Systems, Inc. DCTH

We also want to quickly point out what may very well be another prime bottom-play setup for DCTH. We’ve annotated the chart snapshot below to illustrate why we’ll be tracking this one as well as we head through midweek.

Extended Watchlist:

Incoming search terms:

  • dtch stock

Blue Horseshoe Stocks: MCIG Review & More

mCig, Inc. MCIG

The first thing we want to do to kick off the short trading week, is rehash the recent performance of MCIG. In our first report of the year, we were reminding our members of our ongoing interest in the cannabis sector and related fields, and gave a laundry list of plays that we wanted to track going forward from that point.

The following morning, we would observe a low of .1599 in MCIG, before it began a two week bullish run, and it hasn’t looked back since.

On Friday, MCIG attained a new three-year high of .38, where it also closed. That works out to an overall increase of 138% that we’ve witnessed with MCIG in the first two weeks of 2017. With the strong close, we’ll be sure to watch its activity closely as we head into the third.

Retractable Technologies, Inc. RVP

The next thing crossing our screens that we feel warrants some attention is the present situation with RVP. We took notice of a Form-4 filing last week, alluding to the purchase of a large block of shares by the CEO.  Thomas Shaw picked up two million shares at .89, just a penny above the stock’s four-year low of .88, which was recorded on Friday.

With listing standards stipulating the maintenance of a PPS of at least a dollar, and the added confidence engendered by an executive placing faith in his stock through purchase on the open market, we feel RVP has the makings of a prime bottom-play, and we’ll be very interested to track its progress in this regard.

Extended Watchlist: